Systems prediction of chronic lung allograft dysfunction: Results and perspectives from the Cohort of Lung Transplantation and Systems prediction of Chronic Lung Allograft Dysfunction cohorts.
Frontiers in medicine
bronchiolitis obliterans syndrome
chronic lung allograft dysfunction
chronic rejection
pulmonary section
restrictive allograft syndrome
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
12
2022
accepted:
07
02
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Chronic lung allograft dysfunction (CLAD) is the leading cause of poor long-term survival after lung transplantation (LT). Systems prediction of Chronic Lung Allograft Dysfunction (SysCLAD) aimed to predict CLAD. To predict CLAD, we investigated the clinicome of patients with LT; the exposome through assessment of airway microbiota in bronchoalveolar lavage cells and air pollution studies; the immunome with works on activation of dendritic cells, the role of T cells to promote the secretion of matrix metalloproteinase-9, and subpopulations of T and B cells; genome polymorphisms; blood transcriptome; plasma proteome studies and assessment of MSK1 expression. Clinicome: the best multivariate logistic regression analysis model for early-onset CLAD in 422 LT eligible patients generated a ROC curve with an area under the curve of 0.77. Exposome: chronic exposure to air pollutants appears deleterious on lung function levels in LT recipients (LTRs), might be modified by macrolides, and increases mortality. Our findings established a link between the lung microbial ecosystem, human lung function, and clinical stability post-transplant. Immunome: a decreased expression of CLEC1A in human lung transplants is predictive of the development of chronic rejection and associated with a higher level of interleukin 17A; Immune cells support airway remodeling through the production of plasma MMP-9 levels, a potential predictive biomarker of CLAD. Blood CD9-expressing B cells appear to favor the maintenance of long-term stable graft function and are a potential new predictive biomarker of BOS-free survival. An early increase of blood CD4 + CD57 + ILT2+ T cells after LT may be associated with CLAD onset. Genome: Donor Club cell secretory protein G38A polymorphism is associated with a decreased risk of severe primary graft dysfunction after LT. Transcriptome: blood POU class 2 associating factor 1, T-cell leukemia/lymphoma domain, and B cell lymphocytes, were validated as predictive biomarkers of CLAD phenotypes more than 6 months before diagnosis. Proteome: blood A2MG is an independent predictor of CLAD, and MSK1 kinase overexpression is either a marker or a potential therapeutic target in CLAD. Systems prediction of Chronic Lung Allograft Dysfunction generated multiple fingerprints that enabled the development of predictors of CLAD. These results open the way to the integration of these fingerprints into a predictive handprint.
Sections du résumé
Background
UNASSIGNED
Chronic lung allograft dysfunction (CLAD) is the leading cause of poor long-term survival after lung transplantation (LT). Systems prediction of Chronic Lung Allograft Dysfunction (SysCLAD) aimed to predict CLAD.
Methods
UNASSIGNED
To predict CLAD, we investigated the clinicome of patients with LT; the exposome through assessment of airway microbiota in bronchoalveolar lavage cells and air pollution studies; the immunome with works on activation of dendritic cells, the role of T cells to promote the secretion of matrix metalloproteinase-9, and subpopulations of T and B cells; genome polymorphisms; blood transcriptome; plasma proteome studies and assessment of MSK1 expression.
Results
UNASSIGNED
Clinicome: the best multivariate logistic regression analysis model for early-onset CLAD in 422 LT eligible patients generated a ROC curve with an area under the curve of 0.77. Exposome: chronic exposure to air pollutants appears deleterious on lung function levels in LT recipients (LTRs), might be modified by macrolides, and increases mortality. Our findings established a link between the lung microbial ecosystem, human lung function, and clinical stability post-transplant. Immunome: a decreased expression of CLEC1A in human lung transplants is predictive of the development of chronic rejection and associated with a higher level of interleukin 17A; Immune cells support airway remodeling through the production of plasma MMP-9 levels, a potential predictive biomarker of CLAD. Blood CD9-expressing B cells appear to favor the maintenance of long-term stable graft function and are a potential new predictive biomarker of BOS-free survival. An early increase of blood CD4 + CD57 + ILT2+ T cells after LT may be associated with CLAD onset. Genome: Donor Club cell secretory protein G38A polymorphism is associated with a decreased risk of severe primary graft dysfunction after LT. Transcriptome: blood POU class 2 associating factor 1, T-cell leukemia/lymphoma domain, and B cell lymphocytes, were validated as predictive biomarkers of CLAD phenotypes more than 6 months before diagnosis. Proteome: blood A2MG is an independent predictor of CLAD, and MSK1 kinase overexpression is either a marker or a potential therapeutic target in CLAD.
Conclusion
UNASSIGNED
Systems prediction of Chronic Lung Allograft Dysfunction generated multiple fingerprints that enabled the development of predictors of CLAD. These results open the way to the integration of these fingerprints into a predictive handprint.
Identifiants
pubmed: 36968829
doi: 10.3389/fmed.2023.1126697
pmc: PMC10033762
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1126697Informations de copyright
Copyright © 2023 Pison, Tissot, Bernasconi, Royer, Roux, Koutsokera, Coiffard, Renaud-Picard, Le Pavec, Mordant, Demant, Villeneuve, Mornex, Nemska, Frossard, Brugière, Siroux, Marsland, Foureau, Botturi, Durand, Pellet, Danger, Auffray, Brouard, Nicod, Magnan and Members of the COhort of Lung Transplantation and Systems prediction of Chronic Lung Allograft Dysfunction consortia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Thorax. 2011 Sep;66(9):748-54
pubmed: 21429899
Mol Cell. 2000 Aug;6(2):395-407
pubmed: 10983986
Respir Res. 2017 Dec 13;18(1):208
pubmed: 29237464
PLoS One. 2014 Oct 20;9(10):e109291
pubmed: 25329529
Biomark Insights. 2008 Jun 6;3:351-359
pubmed: 19578518
J Heart Lung Transplant. 2014 Feb;33(2):127-33
pubmed: 24374027
Curr Opin Organ Transplant. 2022 Jun 1;27(3):177-183
pubmed: 35649108
Cell. 1992 Oct 16;71(2):231-41
pubmed: 1423591
J Heart Lung Transplant. 2018 Jun;37(6):770-781
pubmed: 29571601
J Heart Lung Transplant. 2020 Aug;39(8):771-773
pubmed: 32620449
J Heart Lung Transplant. 2020 Oct;39(10):1003-1015
pubmed: 32811772
Curr Opin Organ Transplant. 2020 Dec;25(6):563-567
pubmed: 33105199
Am J Transplant. 2015 Sep;15(9):2288-300
pubmed: 26234373
Am J Respir Crit Care Med. 2015 Mar 15;191(6):656-64
pubmed: 25590631
Am J Respir Crit Care Med. 2016 Nov 15;194(10):1252-1263
pubmed: 27248293
Am J Respir Crit Care Med. 2007 Mar 1;175(5):507-13
pubmed: 17158279
J Heart Lung Transplant. 2022 May;41(5):626-640
pubmed: 35181243
J Clin Invest. 2010 Jun;120(6):1836-47
pubmed: 20501946
Eur Respir J. 2014 Mar;43(3):689-93
pubmed: 24585866
Curr Opin Pulm Med. 2019 May;25(3):308-316
pubmed: 30883449
Am J Transplant. 2005 Jun;5(6):1548-52
pubmed: 15888067
Am J Physiol Lung Cell Mol Physiol. 2016 Oct 1;311(4):L696-L703
pubmed: 27496897
Transplantation. 2021 Jun 1;105(6):1212-1224
pubmed: 33560725
Am J Transplant. 2016 Apr;16(4):1102-12
pubmed: 26603381
J Heart Lung Transplant. 2022 Aug;41(8):1063-1074
pubmed: 35690561
J Heart Lung Transplant. 2021 Feb;40(2):108-119
pubmed: 33317956
Sarcoidosis Vasc Diffuse Lung Dis. 2013 Mar;30(1):28-35
pubmed: 24003532
Rev Mal Respir. 2018 Sep;35(7):699-705
pubmed: 30100530
Nat Commun. 2021 Apr 9;12(1):2126
pubmed: 33837203
Cochrane Database Syst Rev. 2013 Nov 27;(11):CD008927
pubmed: 24282128
Am J Transplant. 2008 Sep;8(9):1911-20
pubmed: 18786233
Front Immunol. 2018 Sep 26;9:2216
pubmed: 30319655
Transplantation. 2018 Aug;102(8):1382-1390
pubmed: 29470356
Am J Transplant. 2017 Jun;17(6):1502-1514
pubmed: 27982503
Transplantation. 2016 Sep;100(9):1803-14
pubmed: 27257997
Science. 1990 Jan 19;247(4940):332-6
pubmed: 2404338
J Am Soc Nephrol. 2015 Oct;26(10):2588-98
pubmed: 25644114
J Heart Lung Transplant. 2021 Nov;40(11):1349-1379
pubmed: 34419372
J Heart Lung Transplant. 2019 May;38(5):483-492
pubmed: 31027539
Am J Transplant. 2014 Dec;14(12):2749-57
pubmed: 25358842
J Heart Lung Transplant. 2021 Oct;40(10):1060-1072
pubmed: 34446355
Am J Transplant. 2011 Mar;11(3):561-7
pubmed: 21299834
Blood Adv. 2017 Mar 22;1(9):557-568
pubmed: 29296975
J Heart Lung Transplant. 2019 May;38(5):493-503
pubmed: 30962148
Clin Transplant. 2020 Feb;34(2):e13781
pubmed: 31958356
J Allergy Clin Immunol. 2015 Jan;135(1):277-80
pubmed: 25445821
J Heart Lung Transplant. 2020 Dec;39(12):1338-1340
pubmed: 33250117
Eur J Epidemiol. 2013 Apr;28(4):347-55
pubmed: 23546766
Am J Transplant. 2014 Feb;14(2):446-52
pubmed: 24400993
BMJ Open. 2021 Oct 7;11(10):e052138
pubmed: 34620664
J Heart Lung Transplant. 2020 Aug;39(8):761-770
pubmed: 32418864
Front Immunol. 2019 Jul 17;10:1681
pubmed: 31379869
J Allergy Clin Immunol. 2018 Feb;141(2):718-729.e7
pubmed: 28729000
Eur Respir J. 2017 Jan 18;49(1):
pubmed: 28100545
Front Immunol. 2021 May 26;12:689420
pubmed: 34122454
Am J Transplant. 2019 Nov;19(11):3162-3175
pubmed: 31305014
J Clin Invest. 2010 Jun;120(6):1848-61
pubmed: 20501943
Am J Transplant. 2015 Feb;15(2):461-71
pubmed: 25488753
Eur Respir J. 2017 Jan 18;49(1):
pubmed: 27836956
Lancet Digit Health. 2021 Dec;3(12):e795-e805
pubmed: 34756569
Curr Opin Organ Transplant. 2022 Feb 1;27(1):1-6
pubmed: 34939958
Front Immunol. 2018 Jan 11;8:1841
pubmed: 29375549
Am J Transplant. 2005 Aug;5(8):2022-30
pubmed: 15996255
J Inflamm Res. 2020 Nov 30;13:1021-1028
pubmed: 33299339
Front Med (Lausanne). 2017 Jul 17;4:109
pubmed: 28770204